clinical trial · NCT07188844
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH·phase2·enrolling by invitation·n = 108
Chronic Inflammatory Demyelinating PolyneuropathyBatoclimab
brief summary
This is an open-label extension (OLE) study designed to evaluate the long-term safety and tolerability of batoclimab in participants with CIDP who have completed Study IMVT-1401-2401 (NCT05581199). In this study, participants will receive 340 mg of batoclimab subcutaneously (SC) once weekly (QW) for up to 52 weeks. Upon completion of the Week 52 or early termination (ET) Visit, participants will transition into the 4-week Follow-up Period, which concludes with a Follow-up Visit approximately 28 (± 7) days after the Week 52 or ET Visit.
started
Aug 28, 2025
primary completion
Nov 1, 2028
completion
Nov 1, 2028
last updated
Dec 26, 2025
official title
An Open-Label Extension Study to Assess Long-term Safety and Tolerability of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol